health benefits of microdosing tirzepatide Microdosing: The Growing Off-Label Trend You Should Know About Microdosing Tirzepatide: An Innovative Approach

No other participants were involved in the research process

The rate of discontinuation due to any adverse event in the dose escalation groups was approximately 11%, with GI-related events accounting for less than 8%

The mean pre-operative BMI was 46.7 kg/m2, decreasing to 33.4 kg/m2 post-operatively

J Mol Biol (2009) 391:53651

Growth Hormone and Insulin-Like Growth Factor-1 (IGF-1) GH and its downstream effector, insulin-like growth factor-1 (IGF-1), have become popular agents among athletes aiming to enhance lean body mass, accelerate recovery, and improve exercise performanceoften in combination with insulin or anabolic steroids